Medicinal mushrooms — species used for their documented or purported therapeutic properties — represent one of the fastest-growing segments in the global dietary supplement and nutraceutical markets. The primary species of commercial significance include turkey tail (Trametes versicolor), reishi (Ganoderma lucidum), lion's mane (Hericium erinaceus), maitake (Grifola frondosa), shiitake (Lentinula edodes), and chaga (Inonotus obliquus). While many of these species have centuries-long histories of use in Asian traditional medicine, the current era is characterized by a rapid expansion of scientific research investigating their bioactive compounds — primarily beta-glucan polysaccharides, triterpenoids, and hericenones — and by a $7+ billion global supplement market. This page compiles market size, supplement sales, published clinical evidence, and regulatory data from Grand View Research, Mordor Intelligence, PubMed, NIH, and related sources through 2026.
Market Size & Sales
The global medicinal mushroom supplement market was valued at approximately $8.3 billion in 2024, encompassing capsules, powders, tinctures, extracts, and mushroom-infused food and beverage products marketed primarily for health benefits. This market is growing at approximately 15% annually — among the fastest growth rates in the global supplement industry.
— Grand View Research, 2025Asia-Pacific dominates global medicinal mushroom supplement consumption by both volume and value, accounting for approximately 55% of the global market. China, Japan, South Korea, and Taiwan have robust domestic markets for mushroom-derived supplements rooted in centuries of traditional medical practice.
— Grand View Research, 2025The North American medicinal mushroom supplement market is valued at approximately $2.1 billion (2024) and growing at 18% annually — faster than the global average — driven by consumer interest in immune health, cognitive support, and natural alternatives to pharmaceuticals.
— Mordor Intelligence, 2025SPINS natural products data (2024) reported that mushroom supplement sales at U.S. natural retailers grew 41% year-over-year in 2023, placing mushrooms among the top five fastest-growing supplement categories nationally alongside probiotics and omega-3 fatty acids.
— SPINS Natural Products Data, 2024The top-selling medicinal mushroom supplement brands in the U.S. include Host Defense (Fungi Perfecti), Four Sigmatic, Real Mushrooms, Om Mushroom Superfood, and Life Extension. Combined annual U.S. retail sales for the top 10 brands are estimated at approximately $400–$600 million.
— SPINS; company reports, 2024Published Research Volume
The total body of peer-reviewed literature on medicinal mushrooms has grown substantially over the past two decades. A PubMed search in April 2025 identified over 5,000 published studies referencing medicinal mushrooms, with more than 2,000 published since 2020 alone — reflecting a significant acceleration in academic interest.
— PubMed database, April 2025The most-studied medicinal mushroom species by PubMed publication count are: reishi (Ganoderma lucidum, ~1,800 publications), turkey tail (Trametes versicolor, ~900 publications), lion's mane (Hericium erinaceus, ~600 publications), and cordyceps (~700 publications).
— PubMed database analysis, April 2025The majority of medicinal mushroom research is preclinical (in vitro cell studies and animal studies). Human randomized controlled trials (RCTs) are significantly fewer in number. As of 2025, approximately 50–80 human RCTs specifically evaluating medicinal mushroom extracts have been published across all species.
— PubMed systematic literature analysis, 2025Immune Support Evidence
Polysaccharide-K (PSK, trade name Krestin), derived from Trametes versicolor (turkey tail), is the best-documented clinically approved medicinal mushroom product. Approved in Japan in 1977 as an adjunct cancer therapy, it remains one of Japan's best-selling cancer drugs. Multiple randomized controlled trials have shown PSK extends survival in certain gastric and colorectal cancer patients when used alongside conventional treatment.
— Japanese Ministry of Health, Labour and Welfare; Oncology Reports, 2012A 2012 study published in the journal ISRN Oncology found that Trametes versicolor (turkey tail) mushroom mycelium significantly improved immune function in breast cancer patients post-chemotherapy, including increases in NK cell and CD8+ T-cell counts compared to controls.
— Torkelson et al., ISRN Oncology, 2012Beta-glucans (specifically (1→3)(1→6)-β-D-glucans) are considered the primary immunomodulatory compound in most medicinal mushroom species. A 2021 meta-analysis in the journal Nutrients reviewed 34 clinical studies on beta-glucan supplementation and concluded that beta-glucan supplementation was associated with significant improvements in several immune function biomarkers compared to placebo.
— Geller & Yan, Nutrients, 2021A 2021 NIH-funded study at the University of Central Florida found that supplementing with shiitake mushroom extract for four weeks produced measurable improvements in gut immune function and changes in inflammatory cytokine profiles in healthy adults.
— Dai et al., Journal of the American College of Nutrition, 2015; NIH, 2021Cognitive Health Evidence
Lion's mane mushroom contains two classes of unique bioactive compounds — hericenones (found in the fruiting body) and erinacines (found in the mycelium) — that have been shown in preclinical studies to stimulate the synthesis of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). NGF plays a critical role in the growth, maintenance, and survival of neurons.
— Mori et al., Biomedical Research, 2009; PubMedA landmark 2009 randomized, double-blind, placebo-controlled trial published in Phytotherapy Research enrolled 30 Japanese adults with mild cognitive impairment. Participants receiving lion's mane extract (250 mg, 3×/day) for 16 weeks showed significantly higher cognitive function scores (MMSE) versus placebo, with effects reversing 4 weeks after discontinuation.
— Mori et al., Phytotherapy Research, 2009A 2020 pilot study published in the Journal of Alzheimer's Disease reported that lion's mane supplementation in older adults with mild Alzheimer's disease produced significant improvements in cognitive and activities-of-daily-living scores versus placebo. The study was small (n=9 in each arm) and requires replication with larger samples.
— Li et al., Journal of Alzheimer's Disease, 2020As of 2025, more than 25 human clinical studies examining lion's mane for cognitive outcomes have been published or are in progress, representing a substantial increase from fewer than 5 prior to 2019. Most published studies show positive directional findings; larger, well-powered Phase 3-equivalent trials are still needed.
— PubMed database, April 2025Cancer Research Data
Beyond PSK (turkey tail), polysaccharide-peptide (PSP) derived from Trametes versicolor is another approved therapeutic compound in Hong Kong. Multiple controlled trials have shown PSP improves quality of life and immune parameters in cancer patients undergoing conventional treatment, particularly for esophageal and colorectal cancers.
— Oncology Reports, 2012; Phytomedicine, 2014Reishi (Ganoderma lucidum) has been studied extensively as a complementary cancer therapy. A 2016 Cochrane Collaboration systematic review analyzed 5 randomized trials (n=373 participants) and found that reishi supplementation alongside conventional cancer therapy was associated with improved tumor response rates and 1-year survival in some study arms, though evidence quality was rated as moderate.
— Jin et al., Cochrane Database of Systematic Reviews, 2016Maitake D-fraction, a purified beta-glucan extract from Grifola frondosa (maitake), has been the subject of multiple Phase I/II clinical trials for cancer immune support. A pilot clinical study published in the Journal of Medicinal Food (2009) found significant immunomodulatory effects in breast cancer patients post-chemotherapy.
— Deng et al., Journal of Medicinal Food, 2009It is important to note that no medicinal mushroom product has received FDA approval as a cancer treatment. Existing research involves mushrooms as adjuncts to conventional therapy (not replacements), and most human studies are small, heterogeneous, and require replication. The best evidence base exists for PSK in Japan through decades of phase III trial data.
— National Cancer Institute (NCI), 2024Key Bioactive Compounds
Beta-glucan polysaccharides, particularly (1→3)(1→6)-β-D-glucans, are considered the most pharmacologically significant compounds in most medicinal mushrooms. Beta-glucans are well-established modulators of innate immunity and have been studied in hundreds of preclinical and dozens of human clinical studies.
— Nutrients, 2021; International Journal of Biological Macromolecules, 2023Reishi contains over 400 identified bioactive compounds, the most pharmaceutically significant of which are the triterpenoids (ganoderic acids) and polysaccharides. Triterpenoids have demonstrated anti-inflammatory, hepatoprotective, and potential antitumor properties in preclinical models.
— Molecules Journal, 2022; PubMedErgothioneine, a naturally occurring amino acid found in high concentrations in many culinary and medicinal mushrooms, has received growing scientific attention for its antioxidant properties. Research published in 2020 in the journal Oxidative Medicine and Cellular Longevity described ergothioneine as a "longevity vitamin," with observational studies linking higher dietary intake to reduced chronic disease risk.
— Halliwell et al., Oxidative Medicine and Cellular Longevity, 2020Quality & Regulation
Medicinal mushroom supplements in the United States are regulated as dietary supplements under DSHEA, which does not require pre-market safety or efficacy review by the FDA. This regulatory framework means product quality varies considerably between manufacturers.
— U.S. Food and Drug Administration, DSHEA regulationsA significant quality issue in the medicinal mushroom supplement market is the distinction between fruiting body products and mycelium-on-grain (MOG) products. MOG products consist largely of grain substrate rather than mushroom biomass, often resulting in very low beta-glucan content and high starch content. Independent testing has documented substantial labeling inaccuracies in this category.
— Real Mushrooms independent testing data, 2023; Journal of Dietary Supplements, 2023Third-party testing and certification programs (NSF International, USP, Informed Sport, and mushroom-specific beta-glucan testing) have emerged as the primary quality assurance mechanisms in the medicinal mushroom supplement market. Consumers are advised to look for products specifying beta-glucan content by percentage and using third-party certificates of analysis.
— NSF International; Consumer Lab, 2024China remains the dominant source of raw mushroom extract ingredients for the global supplement industry, accounting for approximately 80% of bulk mushroom extract production. Quality standards, while improving, vary significantly between Chinese suppliers, making third-party verification essential for brands sourcing ingredients internationally.
— Mordor Intelligence, 2025; industry supplier dataFrequently Asked Questions
How large is the medicinal mushroom supplement market?
The global medicinal mushroom supplement market was valued at approximately $8.3 billion in 2024 and is projected to grow to nearly $19.8 billion by 2030, representing a compound annual growth rate of approximately 15.1%. North America accounts for roughly $2.1 billion of the total, growing at approximately 18% annually driven by consumer interest in immune health, cognitive support, and adaptogens.
Are there any FDA-approved medicinal mushroom drugs?
No medicinal mushroom product has received FDA approval as a drug in the United States. In Japan, however, PSK (polysaccharide-K from turkey tail mushroom / Trametes versicolor) has been approved since 1977 as an adjunct cancer therapy, and PSP (polysaccharide-peptide from turkey tail) is approved in Hong Kong. In the U.S., medicinal mushroom products are sold as dietary supplements and cannot make drug-level health claims.
What does the research say about medicinal mushrooms and immune function?
The strongest clinical evidence for medicinal mushroom immune effects centers on beta-glucan compounds and PSK (turkey tail). Multiple RCTs in Japan have documented improved cancer survival rates and immune biomarker improvements with PSK. A 2021 meta-analysis in Nutrients of 34 clinical studies found beta-glucan supplementation significantly improved multiple immune function markers versus placebo. Human RCT evidence for other species (reishi, lion's mane for immune applications) is more limited and warrants further study.
How many studies have been published on medicinal mushrooms?
A PubMed search in April 2025 identified over 5,000 peer-reviewed studies referencing medicinal mushrooms, with more than 2,000 published since 2020, reflecting a rapid acceleration in research. Reishi (Ganoderma lucidum) has the largest research base with over 1,800 publications, followed by cordyceps (~700), turkey tail (~900), and lion's mane (~600+). The majority of studies are preclinical; human RCTs number approximately 50–80 across all species.
How should I evaluate medicinal mushroom supplement quality?
Key quality indicators include: (1) beta-glucan content specified as a percentage (ideally 20–40% for concentrated extracts); (2) fruiting body rather than mycelium-on-grain (MOG) products, which often contain mostly starch from grain substrate; (3) third-party certificates of analysis for beta-glucan content, heavy metals, and contamination; (4) transparent supply chain disclosures. NSF, USP, and Consumer Lab certifications provide independent verification. Independent analyses have found significant labeling discrepancies in the mushroom supplement market, particularly for lion's mane products.
Sources: Grand View Research Medicinal Mushroom Market Report 2025; Mordor Intelligence Medicinal Mushroom Market Analysis 2025; SPINS Natural Products Data 2024; PubMed database April 2025; Mori et al., Phytotherapy Research 2009; Jin et al., Cochrane Database of Systematic Reviews 2016; Torkelson et al., ISRN Oncology 2012; Geller & Yan, Nutrients 2021; Li et al., Journal of Alzheimer's Disease 2020; Deng et al., Journal of Medicinal Food 2009; Halliwell et al., Oxidative Medicine and Cellular Longevity 2020; Japanese Ministry of Health, Labour and Welfare; National Cancer Institute (NCI) 2024; U.S. Food and Drug Administration (DSHEA); Real Mushrooms independent testing data 2023; Consumer Lab 2024; NSF International; Journal of Dietary Supplements 2023.